Cosmos Health (NASDAQ:COSM) Issues Quarterly Earnings Results

Cosmos Health (NASDAQ:COSM) announced its quarterly earnings data on Wednesday. The company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.05), FiscalAI reports. Cosmos Health had a negative net margin of 29.33% and a negative return on equity of 43.96%. The firm had revenue of $17.93 million for the quarter, compared to analysts’ expectations of $18.82 million.

Cosmos Health Price Performance

NASDAQ COSM opened at $0.28 on Thursday. The company has a market cap of $14.88 million, a PE ratio of -0.47 and a beta of 5.00. The firm’s 50 day moving average price is $0.34 and its 200-day moving average price is $0.45. The company has a debt-to-equity ratio of 0.32, a quick ratio of 0.85 and a current ratio of 1.00. Cosmos Health has a 52-week low of $0.28 and a 52-week high of $1.32.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Cosmos Health in a report on Wednesday, January 21st. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has an average rating of “Sell”.

Institutional Trading of Cosmos Health

Institutional investors have recently modified their holdings of the company. XTX Topco Ltd increased its position in shares of Cosmos Health by 52.1% in the 4th quarter. XTX Topco Ltd now owns 99,610 shares of the company’s stock valued at $50,000 after acquiring an additional 34,117 shares during the period. Renaissance Technologies LLC increased its holdings in shares of Cosmos Health by 260.5% in the fourth quarter. Renaissance Technologies LLC now owns 334,575 shares of the company’s stock valued at $167,000 after purchasing an additional 241,775 shares during the period. Finally, Citadel Advisors LLC raised its stake in shares of Cosmos Health by 133.1% in the third quarter. Citadel Advisors LLC now owns 225,507 shares of the company’s stock worth $250,000 after purchasing an additional 128,776 shares during the last quarter. 12.61% of the stock is currently owned by institutional investors.

Cosmos Health Company Profile

Cosmos Health Inc manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, Cayman Islands, and Cyprus. It offers medicines, OTC medicines, nutraceutical products, vitamins, minerals and dietary, health care products, medical devices, baby products, and others under the Sky Premium Life and Mediterranation brand names. The company serves wholesale distributors and other healthcare providers, such as clinics, government agencies, independent retail and specialty pharmacies and independent specialty distributors.